/
DCF Valuation
Base-case fair value
$9.96
Intrinsic $13.28 · 25% MOS
Current price: $6.00
Base-case summary
Our base-case DCF for Harvard Bioscience Inc (HBIO) projects 10 years of free cash flow growth at 20.0% for years 1–5 and 10.0% for years 6–10, anchored to 95.4% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $2M in trailing free cash flow, this produces an intrinsic value of $13.28 per share. A 25% safety margin gives a fair value of $9.96, suggesting the stock is currently 66% undervalued against the $6.00 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$2M
Cash & equivalents
$7M
Total debt
$44M
Shares outstanding
4M